NuCana's Groundbreaking Presentation at ESMO Congress
NuCana plc (NASDAQ: NCNA) has captured attention with its compelling findings from the Phase 2 NuTide:701 study, which examines the use of NUC-7738 in tandem with pembrolizumab. This innovative study, shared at the ESMO Congress, focuses specifically on those battling metastatic melanoma who have not responded to previous PD-1 inhibitor therapies.
Notable Patient Results
Among the 12 patients included in the study, many having already attempted two or more lines of PD-1 inhibitor treatments, a remarkable 75%—which translates to nine patients—successfully achieved disease control. This group included two patients who experienced Partial Responses. One particularly noteworthy case involved a patient who had received two prior treatments and had shown progressive disease just two months after the latest therapy with ipilimumab and nivolumab. This individual saw tumor volume decrease by an impressive 55%. Additionally, seven out of the 12 participants enjoyed progression-free survival of over five months, a significant improvement compared to the expected outcomes in this challenging group.
How NUC-7738 Works
NUC-7738 has the capacity to re-sensitize tumors that are resistant to PD-1 inhibitors. This unique ability is believed to stem from its mechanism of action, which targets various aspects of the tumor microenvironment (TME). It disrupts RNA polyadenylation, leading to profound alterations in gene expression within cancer cells. Insights from tumor biopsies taken before and after treatment with NUC-7738 revealed significant increases in genes important for antigen presentation and T-cell activation, bolstering the treatment's efficacy.
Insights from NuCana's Leadership
Hugh S. Griffith, the Founder and Chief Executive Officer of NuCana, expressed his excitement: “We are delighted to share these findings about the synergistic effects of NUC-7738 alongside pembrolizumab in patients with PD-1 inhibitor refractory melanoma. Current available treatments provide bleak results, with a median progression-free survival of just 2-3 months. Therefore, we are encouraged by the number of our patients who have achieved progression-free survival of over five months.”
Broader Impact on Cancer Treatment
Griffith further stated, “The translational data from this study matches our earlier non-clinical research and reinforces our belief that NUC-7738 can effectively make previously resistant tumors more amenable to PD-1 inhibitors by targeting various facets of the tumor microenvironment. Moreover, our research on NUC-7738 across different tumor types suggests its effects may extend beyond just melanoma. We look forward to sharing more about our strategic development plans for NUC-7738 in the future.”
About NuCana and Their Innovative Technology
NuCana is dedicated to improving treatment outcomes for cancer patients through its state-of-the-art ProTide technology. This innovative method aims to enhance some of the most commonly used chemotherapy agents, particularly nucleoside analogs, turning them into safer, more effective therapeutic options. While traditional treatments are often foundational in cancer care, they've got significant limitations. By harnessing its proprietary technology, NuCana aims to develop new drugs—termed ProTides—that address the weaknesses of standard nucleoside analogs, ensuring effective delivery of higher concentrations of anti-cancer metabolites to cancer cells.
NuCana's Promising Development Pipeline
NuCana’s future looks bright with two main therapeutic candidates: NUC-3373 and NUC-7738. NUC-3373, derived from the well-known chemotherapy drug 5-fluorouracil, is making strides in several clinical trials. These include the NuTide:302 Phase 1b/2 study, which explores its efficacy alongside leucovorin, irinotecan or oxaliplatin, and bevacizumab for metastatic colorectal cancer, as well as the NuTide:303 trial assessing its use with pembrolizumab for advanced solid tumors. Meanwhile, NUC-7738 is undergoing evaluation for its unique anti-cancer effects as both a standalone treatment and when combined with pembrolizumab in melanoma patients as part of the Phase 2 segment of the ongoing Phase 1/2 NuTide:701 study.
Frequently Asked Questions
What is NUC-7738?
NUC-7738 is an anti-cancer drug developed by NuCana that targets RNA polyadenylation and alters gene expression in cancer cells, aiming to re-sensitize tumors that are resistant to treatment.
What are the key findings of the study?
The study demonstrated that 75% of patients achieved disease control, with one patient experiencing a 55% reduction in tumor volume and several individuals enjoying progression-free survival of over five months.
Who is NuCana?
NuCana is a clinical-stage biopharmaceutical company dedicated to improving cancer treatment outcomes by developing innovative therapies that enhance traditional chemotherapy agents.
What other therapies are in development at NuCana?
NuCana is also working on NUC-3373, a novel therapy based on 5-fluorouracil, which is currently being studied in various clinical trials to treat several types of cancer, including colorectal and lung cancer.
Why is the timing of this study significant?
The study's presentation at the ESMO Congress highlights the urgent need for effective treatments for patients with resistant melanoma, emphasizing the potential clinical impact of NUC-7738.
